Data quality in rare diseases registries

Yllka Kodra, Manuel Posada De La Paz, Alessio Coi, Michele Santoro, Fabrizio Bianchi, Faisal Ahmed, Yaffa R. Rubinstein, Jérôme Weinbach, Domenica Taruscio

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

In the field of rare diseases, registries are considered power tool to develop clinical research, to facilitate the planning of appropriate clinical trials, to improve patient care and healthcare planning. Therefore high quality data of rare diseases registries is considered to be one of the most important element in the establishment and maintenance of a registry. Data quality can be defined as the totality of features and characteristics of data set that bear on its ability to satisfy the needs that result from the intended use of the data. In the context of registries, the ‘product’ is data, and quality refers to data quality, meaning that the data coming into the registry have been validated, and ready for use for analysis and research. Determining the quality of data is possible through data assessment against a number of dimensions: completeness, validity; coherence and comparability; accessibility; usefulness; timeliness; prevention of duplicate records. Many others factors may influence the quality of a registry: development of standardized Case Report Form and security/safety controls of informatics infrastructure. With the growing number of rare diseases registries being established, there is a need to develop a quality validation process to evaluate the quality of each registry. A clear description of the registry is the first step when assessing data quality or the registry evaluation system. Here we report a template as a guide for helping registry owners to describe their registry.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages149-164
Number of pages16
DOIs
Publication statusPublished - Jan 1 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1031
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Rare Diseases
Registries
Planning
Data Accuracy
Patient Care Planning
Informatics
Research
Maintenance
Clinical Trials
Delivery of Health Care
Safety

Keywords

  • Clinical research registry
  • Data quality indicators
  • Public health registry
  • Quality assurance plan
  • Rare diseases registries
  • Validity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Kodra, Y., Posada De La Paz, M., Coi, A., Santoro, M., Bianchi, F., Ahmed, F., ... Taruscio, D. (2017). Data quality in rare diseases registries. In Advances in Experimental Medicine and Biology (pp. 149-164). (Advances in Experimental Medicine and Biology; Vol. 1031). Springer New York LLC. https://doi.org/10.1007/978-3-319-67144-4_8

Data quality in rare diseases registries. / Kodra, Yllka; Posada De La Paz, Manuel; Coi, Alessio; Santoro, Michele; Bianchi, Fabrizio; Ahmed, Faisal; Rubinstein, Yaffa R.; Weinbach, Jérôme; Taruscio, Domenica.

Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. p. 149-164 (Advances in Experimental Medicine and Biology; Vol. 1031).

Research output: Chapter in Book/Report/Conference proceedingChapter

Kodra, Y, Posada De La Paz, M, Coi, A, Santoro, M, Bianchi, F, Ahmed, F, Rubinstein, YR, Weinbach, J & Taruscio, D 2017, Data quality in rare diseases registries. in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1031, Springer New York LLC, pp. 149-164. https://doi.org/10.1007/978-3-319-67144-4_8
Kodra Y, Posada De La Paz M, Coi A, Santoro M, Bianchi F, Ahmed F et al. Data quality in rare diseases registries. In Advances in Experimental Medicine and Biology. Springer New York LLC. 2017. p. 149-164. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-67144-4_8
Kodra, Yllka ; Posada De La Paz, Manuel ; Coi, Alessio ; Santoro, Michele ; Bianchi, Fabrizio ; Ahmed, Faisal ; Rubinstein, Yaffa R. ; Weinbach, Jérôme ; Taruscio, Domenica. / Data quality in rare diseases registries. Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. pp. 149-164 (Advances in Experimental Medicine and Biology).
@inbook{45185d05579b49adab0a220eef5ba872,
title = "Data quality in rare diseases registries",
abstract = "In the field of rare diseases, registries are considered power tool to develop clinical research, to facilitate the planning of appropriate clinical trials, to improve patient care and healthcare planning. Therefore high quality data of rare diseases registries is considered to be one of the most important element in the establishment and maintenance of a registry. Data quality can be defined as the totality of features and characteristics of data set that bear on its ability to satisfy the needs that result from the intended use of the data. In the context of registries, the ‘product’ is data, and quality refers to data quality, meaning that the data coming into the registry have been validated, and ready for use for analysis and research. Determining the quality of data is possible through data assessment against a number of dimensions: completeness, validity; coherence and comparability; accessibility; usefulness; timeliness; prevention of duplicate records. Many others factors may influence the quality of a registry: development of standardized Case Report Form and security/safety controls of informatics infrastructure. With the growing number of rare diseases registries being established, there is a need to develop a quality validation process to evaluate the quality of each registry. A clear description of the registry is the first step when assessing data quality or the registry evaluation system. Here we report a template as a guide for helping registry owners to describe their registry.",
keywords = "Clinical research registry, Data quality indicators, Public health registry, Quality assurance plan, Rare diseases registries, Validity",
author = "Yllka Kodra and {Posada De La Paz}, Manuel and Alessio Coi and Michele Santoro and Fabrizio Bianchi and Faisal Ahmed and Rubinstein, {Yaffa R.} and J{\'e}r{\^o}me Weinbach and Domenica Taruscio",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-67144-4_8",
language = "English",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "149--164",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Data quality in rare diseases registries

AU - Kodra, Yllka

AU - Posada De La Paz, Manuel

AU - Coi, Alessio

AU - Santoro, Michele

AU - Bianchi, Fabrizio

AU - Ahmed, Faisal

AU - Rubinstein, Yaffa R.

AU - Weinbach, Jérôme

AU - Taruscio, Domenica

PY - 2017/1/1

Y1 - 2017/1/1

N2 - In the field of rare diseases, registries are considered power tool to develop clinical research, to facilitate the planning of appropriate clinical trials, to improve patient care and healthcare planning. Therefore high quality data of rare diseases registries is considered to be one of the most important element in the establishment and maintenance of a registry. Data quality can be defined as the totality of features and characteristics of data set that bear on its ability to satisfy the needs that result from the intended use of the data. In the context of registries, the ‘product’ is data, and quality refers to data quality, meaning that the data coming into the registry have been validated, and ready for use for analysis and research. Determining the quality of data is possible through data assessment against a number of dimensions: completeness, validity; coherence and comparability; accessibility; usefulness; timeliness; prevention of duplicate records. Many others factors may influence the quality of a registry: development of standardized Case Report Form and security/safety controls of informatics infrastructure. With the growing number of rare diseases registries being established, there is a need to develop a quality validation process to evaluate the quality of each registry. A clear description of the registry is the first step when assessing data quality or the registry evaluation system. Here we report a template as a guide for helping registry owners to describe their registry.

AB - In the field of rare diseases, registries are considered power tool to develop clinical research, to facilitate the planning of appropriate clinical trials, to improve patient care and healthcare planning. Therefore high quality data of rare diseases registries is considered to be one of the most important element in the establishment and maintenance of a registry. Data quality can be defined as the totality of features and characteristics of data set that bear on its ability to satisfy the needs that result from the intended use of the data. In the context of registries, the ‘product’ is data, and quality refers to data quality, meaning that the data coming into the registry have been validated, and ready for use for analysis and research. Determining the quality of data is possible through data assessment against a number of dimensions: completeness, validity; coherence and comparability; accessibility; usefulness; timeliness; prevention of duplicate records. Many others factors may influence the quality of a registry: development of standardized Case Report Form and security/safety controls of informatics infrastructure. With the growing number of rare diseases registries being established, there is a need to develop a quality validation process to evaluate the quality of each registry. A clear description of the registry is the first step when assessing data quality or the registry evaluation system. Here we report a template as a guide for helping registry owners to describe their registry.

KW - Clinical research registry

KW - Data quality indicators

KW - Public health registry

KW - Quality assurance plan

KW - Rare diseases registries

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=85037646430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037646430&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-67144-4_8

DO - 10.1007/978-3-319-67144-4_8

M3 - Chapter

T3 - Advances in Experimental Medicine and Biology

SP - 149

EP - 164

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -